Eye Changes in Adults With Obesity Using Semaglutide or Tirzepatide
Observes eye structure and blood flow in adults with obesity taking semaglutide or tirzepatide.
Plain-language title generated from the registry record
Registry title: Ocular Changes in Patients Using Tirzepatide or Semaglutide
Key facts
- Where
- Istanbul, TürkiyeSee the site
Where in Türkiye
- Istanbul University, Istanbul Faculty of MedicineIstanbul, TürkiyeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istanbul University
- Trial code
- NCT07924618
- Record updated
- 9 November 2026
- Original description
This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.Read full original descriptionShow less
Evaluation of Optic Nerve Head, Retinal Changes, and Choroidal Blood Flow in Patients With Diabetes and Obesity Using Tirzepatide or Semaglutide
This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.
Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods.
The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.
Inclusion: Age 18 years or older; Diagnosis of obesity; Receiving semaglutide or tirzepatide as part of routine clinical care; Participants with or without type 2 diabetes mellitus; Availability for baseline and follow-up ophthalmologic examinations.
Exclusion: Not receiving semaglutide or tirzepatide; Age under 18 years; Inability to complete the required ophthalmologic examinations or imaging assessments.